Inhibition of cellular alpha-glucosidases results in increased presentation of hepatitis B virus glycoprotein-derived peptides by MHC class I

Virology

Volumn 384, Issue 1, 2009, Pages 12-15

  Simsek, Ender ^a   Sinnathamby, Gomathinayagam ^b   Block, Timothy M ^a,b   Liu, Yuanjie ^a   Philip, Ramila ^b   Mehta, Anand S ^a   Norton, Pamela A ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b BARUCH S BLUMBERG INSTITUTE   (United States)

Author keywords

Cytotoxic T lymphocytes; Glucosidase inhibitor; HBV envelope glycoprotein

Indexed keywords

ALPHA GLUCOSIDASE; CALNEXIN; CASTANOSPERMINE 6 BUTYRATE; ENVELOPE PROTEIN; EPITOPE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; OLIGOSACCHARIDE; PROTEASOME; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; ENZYME INHIBITION; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; IMMUNOMODULATION; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PROTEIN INTERACTION;

ALPHA-GLUCOSIDASES; AMINO ACID SEQUENCE; ANIMALS; ANTIGEN PRESENTATION; GENOME, VIRAL; HEPATITIS B VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS I; L CELLS (CELL LINE); MAJOR HISTOCOMPATIBILITY COMPLEX; MICE; MOLECULAR SEQUENCE DATA; T-LYMPHOCYTES, CYTOTOXIC; TRANSFECTION; VIRAL ENVELOPE PROTEINS; VIRAL PROTEINS;

HEPATITIS B VIRUS;

EID: 58549087715     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2008.11.027     Document Type: Article

References (24)

1. Block T.M., and Jordan R. Iminosugars as possible broad spectrum anti hepatitis virus agents: the glucovirs and alkovirs. Antivir. Chem. Chemother. 12 (2002) 317-325
2. Block T.M., Mehta A.S., Blumberg B.S., and Dwek R.A. Does rapid oligomerization of hepatitis B envelope proteins play a role in resistance to proteasomal degradation and enhance chronicity?. DNA Cell Biol. 25 (2006) 165-170
3. Bruss V. Envelopment of the hepatitis B virus nucleocapsid. Virus Res. 106 (2004) 199-209
4. Butters T.D., Dwek R.A., and Platt F.M. Imino sugar inhibitors for treating the lysosomal glycosphingolipidoses. Glycobiology 15 (2005) 43R-52R
5. Chen Y., Cheng M., and Tian Z. Hepatitis B virus down-regulates expressions of MHC class I molecules on hepatoplastoma cell line. Cell. Mol. Immunol. 3 (2006) 373-378
6. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13 (1995) 29-60
7. Cresswell P. Intracellular surveillance: controlling assembly of MHC class I peptide complexes. Traffic 1 (2001) 301-305
8. Durantel D., Alotte C., and Zoulim F. Glucosidase inhibitors as antiviral agents for hepatitis B and C. Curr. Opin. Investig. Drugs 8 (2007) 125-129
9. Eisenlohr L.C., Huang L., and Golovina T.N. Nat. Rev. Immunol. 7 (2007) 403-410
10. Golovina T.N., Morrison S.E., and Eisenlohr L.C. The impact of misfolding versus targeted degradation on the efficiency of the MHC class I-restricted antigen processing. J. Immunol. 174 (2005) 2763-2769
11. Guidotti L.G., and Chisari F.V. Immunobiology and pathogenesis of viral hepatitis. Annu. Rev. Pathol. Mech. Dis. 1 (2006) 23-61
12. Helenius A., and Aebi M. Intracellular functions of N-linked glycans. Science 291 (2001) 2364-2369
13. Ito Y., Kakumu S., Yoshioka K., Wakita T., Ishikawa T., and Koike K. Cytotoxic T lymphocyte activity to hepatitis B virus DNA-transfected HepG2 cells in patients with chronic hepatitis B. Gastroenterol. Jpn. 28 (1993) 657-665
14. Karttunen J., and Shastri N. Measurement of ligand-induced activation in single viable T cells using the lacZ reporter gene. Proc. Natl. Acad. Sci. U. S. A. 88 (1991) 3972-3976
15. Liu Y., Simsek E., Norton P., Sinnathamby G., Philip R., Block T., Zhou T., and Mehta A. The role of the downstream signal sequences in the maturation of the HBV middle surface glycoprotein: development of a novel therapeutic vaccine candidate. Virology 365 (2007) 10-19
16. Liu Y., Zhou T., Simsek E., Block T., and Mehta A. The degradation pathway for the HBV envelope proteins involves proteolysis prior to degradation via the cytosolic proteasome. Virology 369 (2007) 69-77
17. Mehta A., Lu X., Block T.M., Blumberg B.S., and Dwek R.A. Hepatitis B virus (HBV) envelope glycoproteins vary drastically in their sensitivity to glycan processing: evidence that alteration of a single N-linked glycosylation site can regulate HBV secretion. Proc. Natl. Acad. Sci. U. S. A. 94 5 (1997) 1822-1827
18. Moore S.E., and Spiro R.G. Inhibition of glucose trimming by castanospermine results in rapid degradation of unassembled major histocompatibilty complex class I molecules. J. Biol. Chem. 268 (1993) 3809-3812
19. Norton P.A., Conyers B., Gong Q., Steel L.F., Block T.M., and Mehta A.S. Assays for glucosidase inhibitors with potential antiviral activities: secreted alkaline phosphatase as a surrogate marker. J. Virol. Methods 124 (2005) 167-172
20. Schwarz K., de Giuli R., Schmidtke G., Kostka S., van den Broek M., Kim K.B., Crews C.M., Kraft R., and Groettrup M. The selective proteasome inhibitors lactacystin and epoxomysin can be used to either up- or down-regulate antigen presentation at nontoxic doses. J. Immunol. 164 (2000) 6147-6157
21. Sells M.A., Chen M.L., and Acs G. Production of hepatitis B virus particles in HepG2 cells transfected with cloned hepatitis B virus DNA. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 1005-1009
22. Simsek E., Mehta A., Zhou T., Dwek R.A., and Block T. Hepatitis B virus large and middle glycoproteins are degraded by a proteosome pathway in glucosidase-inhibited cells but not in cells with functional glucosidase enzyme. J. Virol. 79 (2005) 12914-12920
23. Wang J., and Michalak T.I. Inhibition by woodchuck hepatitis virus of class I major histocompatibility complex presentation on hepatocytes is mediated by virus envelope pre-S2 protein and can be reversed by treatment with gamma interferon. J. Virol. 80 (2006) 8541-8553
24. Werr M., and Prange R. Role for calnexin and N-linked glycosylation in the assembly and secretion of hepatitis B virus middle envelope protein particles. J. Virol. 72 (1998) 778-782